Ipsen Geçmiş Kazanç Performansı
Hala bu şirketin son kazanç raporunu inceliyoruz
Geçmiş kriter kontrolleri 3/6
Ipsen şirketinin kazançları yıllık ortalama -7.4% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 5.7% oranında azalan oldu. Gelirler yıllık ortalama 8.1% oranında artan oldu. Ipsen şirketinin öz sermaye getirisi 10.2% olup, net marjı 11.3% dir.
Anahtar bilgiler
-7.42%
Kazanç büyüme oranı
-7.40%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 16.27% |
| Gelir büyüme oranı | 8.10% |
| Özkaynak getirisi | 10.25% |
| Net Marj | 11.29% |
| Sonraki Kazanç Güncellemesi | 30 Jul 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
Anlatı Güncellemesi • May 17
IPN: Future Portfolio Execution And Core Pipeline Will Shape Re Rated Earnings Potential
Analysts have raised Ipsen's price target by €13 to €183, citing updated assumptions around the discount rate, revenue growth, profit margins and future P/E that align with recent upward revisions from major banks. Analyst Commentary Recent research updates point to a more constructive stance on Ipsen, with several bullish analysts revisiting their models and price targets.Anlatı Güncellemesi • Apr 24
IPN: Future Portfolio Execution Will Drive Re Rated Earnings Power Potential
Narrative Update on Ipsen The analyst fair value estimate for Ipsen has been revised from €155 to €183. This reflects analysts' updated assumptions on higher revenue growth, a different discount rate, a higher future P/E and recent price target increases and rating changes across several banks.
Anlatı Güncellemesi • Apr 10
IPN: Oncology Pipeline Progress And Safety Setbacks Will Shape Balanced Future Outlook
Analysts have adjusted the Ipsen price target to €151.94, with recent research pointing to updated revenue growth and profit margin assumptions, as well as fresh Street targets around €160 and €170 as key drivers of the new view. Analyst Commentary Bullish Takeaways Bullish analysts are pointing to higher price targets around €160 and €170, which reflects confidence in Ipsen’s ability to execute on its current pipeline and financial framework despite recent product-specific issues.Anlatı Güncellemesi • Mar 27
IPN: Early Oncology Pipeline And Safety Setbacks Will Shape Future Upside
The analyst fair value estimate for Ipsen has shifted from €143 to about €152, as analysts factor in updated price targets around €160 to €170 and recent rating changes that reflect both the impact of the tazemetostat withdrawal and a focus on the broader pipeline and earnings profile. Analyst Commentary Recent research shows a split view on Ipsen, with some bullish analysts lifting price targets toward €160 to €170, while more cautious voices highlight pipeline depth and valuation risks after the tazemetostat withdrawal.
Anlatı Güncellemesi • Mar 13
IPN: Oncology Setbacks And Limited Late Stage Pipeline Will Constrain Future Upside
The analyst fair value estimate for Ipsen has shifted from €105 to €115, with analysts pointing to recent price target revisions, mixed views on the company’s pipeline depth, and updated assumptions on margins and future P/E levels as key drivers of the change. Analyst Commentary Recent Street research around Ipsen has focused on shifting views of the company’s pipeline and valuation, with mixed reactions to the withdrawal of tazemetostat and differing opinions on the depth of late stage assets.Anlatı Güncellemesi • Feb 27
IPN: Limited Late Stage Pipeline Will Constrain Future Upside Potential
The analyst fair value estimate for Ipsen has moved from €134.80 to €143.00, reflecting updated assumptions on revenue growth, margins, and future P/E, following recent price target changes from banks that now range from about €125 to €170. Analyst Commentary Recent research on Ipsen reflects a mix of optimism and caution, with target prices clustering between about €125 and €170 and ratings spread across Buy, Neutral, and Equal Weight.Anlatı Güncellemesi • Feb 12
IPN: Competitive Pressures And Thin Pipeline Will Shape A Balanced Outlook
Analysts have increased their fair value estimate for Ipsen to about €135 per share from roughly €133, reflecting updated price targets that incorporate a mix of cautious views on the late stage pipeline and concerns around competitive pressures, alongside modest target increases from others. Analyst Commentary Recent research shows a split view on Ipsen, with some analysts trimming expectations and others nudging targets higher.Anlatı Güncellemesi • Jan 29
IPN: Mixed Ratings And Limited Late Stage Assets Will Shape A Balanced Outlook
Narrative Update The updated analyst price target for Ipsen moves modestly higher to about €133 from about €131. Analysts point to slightly stronger revenue growth and margin assumptions, while also flagging ongoing concerns about limited late stage assets and competitive pressure on Somatuline, as reflected in recent mixed rating and target changes from UBS, Barclays, and BNP Paribas Exane.Anlatı Güncellemesi • Jan 15
IPN: Mixed Ratings And Pipeline Setbacks Will Shape A Cautious Yet Balanced Outlook
Our updated fair value estimate for Ipsen edges up from €130.07 to €130.79. This reflects a blend of mixed Street signals, where some analysts point to valuation constraints and pipeline depth, while others lift price targets in line with current expectations.Anlatı Güncellemesi • Dec 21
IPN: Guidance Upgrade And Competitive Pressures Will Shape A Cautious Yet Balanced Outlook
Analysts have reduced their price target on Ipsen from EUR 130.07 to EUR 105.00, citing increased competitive pressure on Somatuline as a key driver of the downgrade. Analyst Commentary Analysts note that the reduced price target reflects a reassessment of Ipsen's risk and reward profile in light of mounting competition for Somatuline, which is expected to weigh on both top line momentum and margin resilience.Anlatı Güncellemesi • Dec 07
IPN: Guidance Upgrade And Competition Concerns Will Shape Balanced Future Outlook
Analysts have trimmed their price target on Ipsen by approximately EUR 1 to around EUR 130, reflecting slightly lower long term growth and margin expectations amid rising competitive pressure on key drug Somatuline. Analyst Commentary Analyst sentiment around Ipsen has turned more cautious, with recent revisions reflecting heightened concern about the sustainability of growth in key endocrine oncology franchises and the implications for valuation.Anlatı Güncellemesi • Nov 22
IPN: Guidance Upgrade And New Approvals Will Support Balanced Outlook
Narrative Update on Ipsen Analysts have maintained their fair value estimate for Ipsen at €130.79 per share. They cite minimal changes in key assumptions and only slight fluctuations in projected growth and profitability.Anlatı Güncellemesi • Nov 07
IPN: Future Opportunities And Risks Are Balanced Following Guidance Upgrade
Narrative Update on Ipsen: Analyst Price Target Adjustment Analysts have raised their price target for Ipsen to €130.79, up from €129.93. This change reflects slight improvements in expected revenue growth and profit margin, despite a marginally higher discount rate.Analiz Makalesi • Oct 28
Ipsen (EPA:IPN) Seems To Use Debt Rather Sparingly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Anlatı Güncellemesi • Oct 24
Global Approvals And Guidance Will Drive Expanded Patient Access Worldwide
Narrative Update on Ipsen: Analyst Price Target Adjustment Analysts have slightly increased their price target for Ipsen from $128.43 to $129.93. This adjustment is attributed to minor shifts in revenue growth forecasts and updated profit margin estimates.Anlatı Güncellemesi • Sep 25
Pipeline Catalysts And Approvals Will Expand Global Access
Driven by a modest uptick in consensus revenue growth forecasts and a slight increase in the projected future P/E, Ipsen’s analyst price target has inched up from €127.00 to €128.43. What's in the News Ipsen received Japanese regulatory approval for Bylvay (odevixibat) for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC), with commercialization managed by Ipsen in Japan.Analiz Makalesi • Sep 07
Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 41%?
Key Insights Ipsen's estimated fair value is €205 based on 2 Stage Free Cash Flow to Equity Current share price of €120...Analiz Makalesi • Jul 13
Investors Interested In Ipsen S.A.'s (EPA:IPN) Earnings
Ipsen S.A.'s ( EPA:IPN ) price-to-earnings (or "P/E") ratio of 24.5x might make it look like a strong sell right now...
Yeni Anlatı • Feb 23
Cabometyx And Tovorafenib Approvals May Strengthen Oncology Portfolio In 2025
Expansion of Onivyde and new product approvals could significantly increase revenue and strengthen market positions in key medical segments.Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Ipsen nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Dec 25 | 3,929 | 444 | 1,164 | 754 |
| 30 Sep 25 | 3,845 | 446 | 1,142 | 741 |
| 30 Jun 25 | 3,760 | 448 | 1,206 | 728 |
| 31 Mar 25 | 3,667 | 402 | 1,190 | 707 |
| 31 Dec 24 | 3,575 | 356 | 1,089 | 687 |
| 30 Jun 24 | 3,435 | 664 | 1,157 | 653 |
| 31 Mar 24 | 3,371 | 641 | 1,146 | 636 |
| 31 Dec 23 | 3,306 | 617 | 1,135 | 619 |
| 30 Jun 23 | 3,282 | 406 | 1,105 | 528 |
| 31 Mar 23 | 3,219 | 500 | 1,072 | 487 |
| 31 Dec 22 | 3,156 | 593 | 1,039 | 445 |
| 30 Sep 22 | 3,053 | 656 | 1,007 | 436 |
| 30 Jun 22 | 2,950 | 719 | 975 | 427 |
| 31 Mar 22 | 2,849 | 675 | 946 | 425 |
| 31 Dec 21 | 2,749 | 631 | 916 | 424 |
| 30 Sep 21 | 2,712 | 626 | 923 | 422 |
| 30 Jun 21 | 2,676 | 622 | 931 | 420 |
| 31 Mar 21 | 2,681 | 585 | 951 | 413 |
| 31 Dec 20 | 2,686 | 548 | 972 | 406 |
| 30 Sep 20 | 2,697 | 249 | 986 | 404 |
| 30 Jun 20 | 2,707 | -50 | 1,000 | 403 |
| 31 Mar 20 | 2,700 | -53 | 1,010 | 396 |
| 31 Dec 19 | 2,693 | -55 | 1,021 | 389 |
| 30 Sep 19 | 2,605 | 176 | 1,003 | 363 |
| 30 Jun 19 | 2,516 | 406 | 986 | 337 |
| 31 Mar 19 | 2,432 | 397 | 970 | 319 |
| 31 Dec 18 | 2,348 | 388 | 954 | 302 |
| 30 Sep 18 | 2,258 | 365 | 931 | 292 |
| 30 Jun 18 | 2,167 | 343 | 909 | 281 |
| 31 Mar 18 | 2,090 | 307 | 883 | 274 |
| 31 Dec 17 | 2,012 | 270 | 858 | 266 |
| 30 Sep 17 | 1,923 | 243 | 821 | 264 |
| 30 Jun 17 | 1,834 | 217 | 785 | 262 |
| 31 Mar 17 | 1,753 | 221 | 752 | 247 |
| 31 Dec 16 | 1,671 | 226 | 719 | 231 |
| 30 Sep 16 | 1,623 | 229 | 703 | 214 |
| 30 Jun 16 | 1,575 | 233 | 687 | 196 |
| 31 Mar 16 | 1,548 | 211 | 676 | 194 |
| 31 Dec 15 | 1,520 | 189 | 666 | 193 |
| 30 Sep 15 | 1,468 | 165 | 651 | 192 |
| 30 Jun 15 | 1,416 | 140 | 636 | 191 |
Kaliteli Kazançlar: IPN büyük bir tek seferlik zarar ile €411.3M, 31st December, 2025 tarihine ait son 12 aylık mali sonuçları etkiliyor.
Büyüyen Kar Marjı: IPN 'nin mevcut net kar marjları (11.3%) geçen yılın (10%) sinden daha yüksektir.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: IPN şirketinin kazançları son 5 yılda yılda 7.4% oranında azaldı.
Büyüme Hızlandırma: IPN 'un son bir yıldaki kazanç büyümesi ( 24.6% ) 5 yıllık ortalamasını (yıllık -7.4% ) aşıyor.
Kazançlar vs. Sektör: IPN geçen yılki kazanç büyümesi ( 24.6% ) Pharmaceuticals sektörünün 3.9% değerini aştı.
Özkaynak Getirisi
Yüksek ROE: IPN 'nin Özsermaye Getirisi ( 10.2% ) düşük olarak değerlendiriliyor.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/31 02:01 |
| Gün Sonu Hisse Fiyatı | 2026/05/29 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Ipsen S.A. 26 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Richard Silver | Barclays |
| Charles Pitman | Barclays |
| Charles Pitman | Barclays |